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Abstract
Substances, such as alcohol, opiates and cannabis, have been used by humans for millennia. Today, a much wider
range of substances are used for a range of purposes, including the enhancement of performance during univer-
sity studies, sexual experiences, sports, exercise, at celebrations, socializing and the experience of art and music.
Substance use is also associated with a range of harmful effects to the individual and society as a whole. Prohibi-
tions, regulation, prevention and treatment have all been used to protect against this harm. In this commentary, it
is argued that public health interventions should target relevant harms and not to evaluate which aspects of
human endeavors and experiences should be enhanced and which should not. It is argued that interventions
should directly target the harmful effects, using the best available evidence. Two examples are given of substances
that may be altered to prevent serious harm - one for alcohol and one for cannabis. In the case of alcohol, the
addition of dissolved oxygen could reduce both the risk of accidents and the risk of liver damage associated with
alcohol consumption. In the case of cannabis, there is strong indication that the reduction of content Δ-tetrahydro-
cannabinol and the increase of cannabidiol could reduce the risk of psychoses and the addiction associated with
its use. The aim of this article is to show that responsible regulation should not necessarily be restricted to pre-
venting the use and/or (in the case of alcohol) a reduction in the amounts and frequency of its use, but should
also aim to include a range of other strategies that could reduce the burden of illness associated with illicit sub-
stance use.
Background
Psychoactive substances such as alcohol, cannabis and
opiates have been used by humans for thousands of
years and, in recent times, a multitude of new sub-
stances have been added to the list of such substances.
The reasons for the use of such substance are diverse.
They range from alleviating pain and hunger, obtaining
contact with a sacred world and intoxication.
In ancient Greek mythology, the god of wine, Diony-
sus, is also known as the liberator [1]. The god was
believed to liberate people from their normal self by
‘madness, ecstasy or wine’.O v e r5 0 0 0y e a r sa g o ,t h e
Sumerians in Mesopotamia called the poppy the ‘joy
plant’ [2]. In recent decades, a number of drugs have
been developed to treat mental disorders. A range of
drugs have also been used to obtain other effects: Silde-
fanil is used by men who do not have erectile
dysfunction [3] and anabolic steroids are being used to
increase the size of muscles [4].
While such substances have been used by humans for
many years, societies have also observed that substance
use leads to problems. In recent centuries, these con-
cerns have lead to national and international legislation
which regulates the production, manufacturing and use
of these substances.
Discussion
Broadening the scope
Currently, substances are being manufactured and
altered in ways that lead to many hazards for those who
use them.
A recent editorial in Nature suggested that one type of
use of substances - the use of drugs to enhance aca-
demic work - should be accepted as a fact and regulated
responsibly, rather than simply rejected as cheating or
dangerous behaviour [5]. II suggest that this view may
be broadened beyond regulating substance use for cog-
nitive enhancement. As drugs are not only used to
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substances may extend beyond these purposes. The
point is that public health researchers, policy makers
and legislators should take responsibility for regulation
of use- not simply reject or accept a particular
substance.
The heart of the problem is the definition of the aims
of these policy makers and legislators. Is the goal of pol-
icy to maintain public order and protect the public from
harm, or is it to define what the accepted view of what
a good life is and how the good citizen should behave?
It is important to discriminate between the prevention
of harm and the definition of a good life and the good
citizen. Although it is not without pitfalls, the prevention
of harm is a legitimate goal of policy and public health.
However, imposing a view of what the good life should
be is more questionable. Public health concerns can be
good reasons to prohibit or restrict the manufacturing
and sale of goods that could be harmful. On the other
hand, public health researchers and policy makers should
not judge what in life should be enhanced. Whether stu-
dents or other people wish to have their cognitive skills
enhanced or if they wish to obtain a state that can be
characterized as ecstatic or even ‘mad’ is not something
that should be the concern of health authorities.
In a modern society, using drugs for the enhancement
of the experience of music, dancing, sex or conversation
at a dinner party, should be no more or less a legitimate
goal of an individual than the enhancement of the ability
to study for an exam.
Substances that affect the body vary in terms of their
harm, including risk of addiction [6], and use of sub-
stances can lead to a variety of adverse health effects
and may negatively affect society [7]. Harm may vary
between substances and both experts and drug users
generally perceive these harms differently from the legis-
lators [8]. It our belief that it should be the harmful
effects of drugs of addiction that should guide decisions
about the regulation of substances rather than the rea-
son for their use. Indeed, the reduction of such harm
should be the very target of policy and research, regard-
less of the intentions of the drug user.
Some examples: changing the contents of substances
used for non–medical purposes
In the following, I shall describe how substances that are
already being used for non-medical purposes may be
changed in ways that can potentially reduce their nega-
tive impacts on individuals and on society as a whole.
The point is that regulation should not target why and
how people use substances but only how the harm asso-
ciated with substance use can be reduced or avoided.
This includes the risk of addiction: since the risk of
addiction varies from drug to drug, it follows that the
ingredients could be altered in ways that increase or
decrease the risk [6].
One substance that can possibly be altered in order to
reduce some of its negative side-effects is alcohol. Alco-
hol is one of the most commonly used intoxicating sub-
stances and contributes substantially to the burden of
illness worldwide. It is estimated that the health risk
associated with alcohol is five times greater than the
burden associated with that of the use of all illicit drugs
combined [9]. In a Korean study, dissolved oxygen was
added to alcoholic beverages [10]. The effect was a
much faster elimination of alcohol in the blood. Poten-
tially, the faster elimination could lead to a much
quicker restoration of normal functioning in social drin-
kers, thus reducing the risk of accidents and other side
effects of alcohol drinking. The addition of oxygen
could also potentially reduce the risk of liver damage
and acute hangover symptoms. The real-life significance
of this finding is unknown and requires further study.
For instance: do alcohol drinkers increase their con-
sumption over a period of drinking in order to maintain
the same blood-alcohol concentration, offsetting the
potential benefits of a manipulated alcohol product?;
and what is the impact of the addition of dissolved oxy-
gen on the risk of developing an addiction?
Another substance that is commonly used in countries
such as the US, southwest Europe and Australia, is can-
nabis [11]. Cannabis is associated with: some risk of
accidents, although less so than alcohol; low birth-
weight of the fetus when smoked during pregnancy; and
some increased risk of diminished cognitive abilities
[11]. There is also considerable evidence that cannabis
use produces sub-clinical psychotic symptoms in regular
users, especially when the age of onset is below 15 [12],
and that cannabis use is a risk factor for subsequent
schizophrenia [13]. While the real-life importance of the
link between cannabis use and psychosis is disputed
[11], the evidence overall points to a dose-dependent
association between cannabis use and the development
of schizophrenia spectrum disorders. However, if canna-
bis products were regulated, the content of cannabis
products could potentially be changed, so that the risk
of psychosis could be reduced [14].
Cannabis contains two important substances
that appear to have almost opposite effects, namely
Δ-tetrahydrocannabinol (THC) and cannabidiol. In an
study of psychotic symptoms among cannabis users,
Morgan and Curran showed that in hair analyses the
use of THC without cannabidiol was strongly correlated
to elevated scores on a scale representing psychosis pro-
neness; when cannabidiol was also present, the scores
became similar to those of non-cannabis using controls
[15]. If cannabis was regulated rather than prohibited, it
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the risk of addiction and psychosis, by balancing the
amount of cannabidiol and THC. The current state of
affairs is that drugs are being bred to contain increasing
amounts of THC [16]. An increase in the amount of
THC used in cannabis may have contributed to an
increase in the disorders which cause cannabis users to
seek medical treatment in the US and many European
countries [11] and the use of these cannabis products is
particularly common among patients who present with
a psychotic disorder [17]. In this way, prohibition may
push cannabis in the wrong direction, making a harmful
drug worse. The regulation of this drug and its ingredi-
ents could make it less harmful.
The implications
The goal of a drug policy (for lack of a better term)
should be the responsible regulation of the range of sub-
stances that have the potential to influence psychologi-
cal and physiological processes. Research can help not
only to identify potential harm and to develop effective
strategies to regulate substances but also to alter sub-
stances or develop new chemical properties which could
result in fewer negative consequences.
Essentially, changes in the content of substances can
be thought of as a parallel to regulating motor vehicles.
Such regulation should not address where people should
drive, or why. However, regulation can make it manda-
tory for cars to have seat belts, rearview mirrors and
other equipment that reduces the risk of accidents.
Changing the harms associated with substances should
obviously not be restricted to changing the chemical
properties of substances. Equally important is the devel-
opment of strategies to control access to substances,
where harm remains a risk. Also, regulating how drugs
can be consumed may sometimes be a feasible strategy.
For instance, if cannabis users can be helped to abandon
smoking and use so-called vaporizers, they will reduce
the amount of carbon-monoxide that they consume
along with cannabis, dramatically reducing the harm
associated with cannabis [18].
Regulating traffic does not eliminate the risks asso-
ciated with traffic. Accidents will always happen and the
driver’s behaviour will still be an immensely important
factor in the risk of accidents. In all likelihood, some
risk will remain with substances that alter the function-
ing of somatic processes, whether they are primarily
located in the brain or primarily located elsewhere. This
risk will vary substantially between users, depending on
their behaviour.
The regulation of the chemical content of substances
that influence bodily processes drugs and the regulation
of price and accessibility should be handled intelligently
and effectively and should not be based on a moral
perspective. The intelligent regulation may at times be a
complete prohibition or a restriction that leads to its
being used for medical purposes only. At other times it
may regulate the contents of substances or where and at
what price they can be sold. Any course of action will
produce costs but they may also produce benefits.
Again, the important thing is to always define which is
the more, and which is the less, harmful course of
action based on the best available evidence.
Conclusion
Substances have been used for millenniums to enhance
experiences and performance. Substance use may also
cause harm, such as accidents, illness and addiction, and
yet some people still choose to use them. The task of
public health interventions should be to target the
health-related harms, but not to evaluate which aspects
of human endeavors and experiences should or should
not be enhanced. Responsible regulation would not
necessarily be restricted to preventing the use of a
potentially harmful substance but may include a range
of other strategies that can reduce the burden of illness
associated with substance use. One example given in
this commentary is the changing of the chemical con-
tent of substances in order to reduce certain risks asso-
ciated with a given substance.
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